Trials / Completed
CompletedNCT05661734
A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain
A Phase 3, Single-arm Study Evaluating the Safety and Effectiveness of VX-548 for Acute Pain
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 258 (actual)
- Sponsor
- Vertex Pharmaceuticals Incorporated · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and effectiveness of VX-548 in treating acute pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Suzetrigine | Tablets for oral administration. |
Timeline
- Start date
- 2023-01-09
- Primary completion
- 2023-12-12
- Completion
- 2023-12-12
- First posted
- 2022-12-22
- Last updated
- 2025-07-01
- Results posted
- 2025-07-01
Locations
14 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05661734. Inclusion in this directory is not an endorsement.